Cysteamine blocks amphetamine-induced deficits in sensorimotor gating

Pharmacology Biochemistry and Behavior

Volumn 58, Issue 3, 1997, Pages 689-693

  Feifel, David ^a   Minor, Kelly L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cysteamine; Dopamine; Prepulse inhibition; Schizophrenia; Sensorimotor gating; Somatostatin

Indexed keywords

AMPHETAMINE; MERCAPTAMINE; SOMATOSTATIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; STARTLE REFLEX;

ACOUSTIC STIMULATION; AMPHETAMINE; ANIMALS; CYSTEAMINE; DOPAMINE UPTAKE INHIBITORS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SOMATOSTATIN; STARTLE REACTION;

EID: 0030868160     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00020-8     Document Type: Article

References (45)

1. Bakhit C., Swerdlow N. Behavioral changes following central injection of cysteamine in rats. Brain Res. 365:1986;159-163.
2. Beal M. F., Martin J. B. The effect of somatostatin on striatal catecholamines. Neurosci. Lett. 44:1984;271-276.
3. Beal M. F., Martin J. B. Effects of neuroleptic drugs on brain somatostatin-like immunoreactivity. Neurosci. Lett. 47:1984;125-130.
4. Bissette G., Widerlov E., Walleus H., Karlsson I, Eklund K., Forsman A., Nemeroff C. Alterations in cerebrospinal fluid concentrations of somatostatin-like immunoreactivity in neuropsychiatric disorders. Arch. Gen. Psychiatry. 43:1986;1148-1151.
5. Braff D. L., Geyer M. A. Sensorimotor gating and schizophrenia. Human and animal model studies Arch. Gen. Psychiatry. 47:1990;181-188.
6. Brown M. R., Fisher L. A., Sawchenko P. E., Swanson L. W., Vale W. W. Biological effects of cysteamine. Relationship to somatostatin depletion Regul. Pept. 5:1983;163-179.
7. Brownstein M., Arimura A., Sato H., Schally A. V., Kizer J. The regional distribution of somatostatin in the rat brain. Endocrinology. 96:1975;1456-1461.
8. Bruno J. F., Xu Y., Song J., Berelowitz M. Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. Endocrinology. 133:1993;2561-2567.
9. Butler R. W., Jenkins M. A., Geyer M. A., Braff D. L. Wisconsin card sorting deficits and diminished sensorimotor gating in a discrete subgroup of schizophrenic patients. Tamminga C. A., Schulz S. C. Advances in neuropsychiatry and psychopharm, vol. 1. 1991;163-168 Reaven Press, Schizophrenia research. New York.
10. Chesselet M. F., Reisine T. D. Somatostatin regulates dopamine release in rat striatal slices and cat caudate nuclei. J. Neurosci. 3:1983;232-236.
11. DeNoble V. J., Hepler D. J., Barto R. A. Cysteamine-induced depletion of somatostatin produces differential cognitive deficits in rats. Brain Res. 482:1989;42-48.
12. Dournaud P., Gu Y. Z., Schonbrunn A., Mazella J., Tannenbaum G. S., Beaudet A. localization of somatostatin receptor SST2A in rat brain using a specific anti-peptide antibody. J. Neurosci. 16:1996;4468-4478.
13. Fendt M., Koch M., Schnitzler H.-U Somatostatin in the pontine reticular formation modulates fear potentiation of the acoustic startle response. An anatomical electrophysiological and behavioral study J. Neurosci. 16:1996;3097-3103.
14. Ferrier N., Roberts G. W., Crow T. J., Johnstone E. C., Owens D., Lee Y. C., O'Shaugnessy D., Adrian T, Polak J, Bloom S. Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sci. 33:1983;475-482.
15. Garcia-Sevilla J. A., Magnusson A. T., Carlsson A. Effect of intracerebroventricularly administered somatostatin on brain monoamine turnover. Brain Res. 155:1978;159-163.
16. Gerner R., Van Kammen D. P., Ninan P. T. Cerebrospinal fluid cholecystokinin, bombesin, and somatostatin in schizophrenia and normals. Prog. Neuropsychopharmacol. Biol. Psychiatry. 9:1985;73-82.
17. Haroutunian V., Mantin R., Campbell G. A., Tsuboyama G. K., Davis K. L. Cysteamine-induced depletion of central somatostatin-like immunoreactivity. Effects on behavior, learning, memory, and brain neurochemistry Brain Res. 403:1987;234-242.
18. Havlicek V., Rezek M., Friesen H. Somatostatin and thyrotropin releasing hormone. Central effect on sleep and motor system Pharmacol. Biochem. Behav. 4:1976;455-459.
19. Kungel M., Friauf E. Somatostatin and leu-enkephalin in the rat auditory brainstem during fetal and postnatal development. Anat. Embryol. 191:1995;425-443.
20. Kungel M., Koch M., Friauf E. Cysteamine impairs the development of the acoustic startle response in rats. Possible role of somatostatin Neurosci. Lett. 202:1996;181-184.
21. Lee N., Radke J. M., Vincent S. R. Intra-cerebral cysteamine infusions attenuate the motor response to dopaminergic agonists. Behav. Brain Res. 29:1988;179-183.
22. Mansbach R. S., Geyer M. A., Braff D. L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berlin). 94:1988;507-514.
23. Martin-Iverson M. T., Radke J. M., Vincent S. R. The effects of cysteamine on dopamine-mediated behaviors. Evidence for dopamine-somatostatin interactions in the striatum Pharmacol. Biochem. Behav. 24:1986;1707-1714.
24. Nemeroff C., Youngblood W. W., Manberg P. J., Prange A. J., Kizer J. S. Brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science. 221:1983;972-974.
25. Palkovits M. M., Brownstein L. E., Eiden L. E., Beinfeld M. C., Russell J., Arimura A., Szabo S. Selective depletion of somatostatin in rat brain by cysteamine. Brain Res. 240:1982;178-180.
26. Plotnikoff N. P., Kastin A. J., Schally A. V. Growth hormone release inhibiting hormone. Neuropharmacological studies Pharmacol. Biochem. Behav. 2:1974;693-696.
27. Radke J. M., MacLennan A. J., Vincent S. R., Fibiger H. C. Comparison between short- and long-term haloperidol administration or somatostatin and substance P concentrations in the rat brain. Brain Res. 480:1989;178-183.
28. Rezek M., Havlicek V., Leybin L., Pinsky C., Kroeger E. A., Hughes K. R., Friesen H. Neostriatal administration of somatostatin. Differential effect of small and large doses on behavior and motor control Can. J. Physiol. Pharmacol. 55:1977;234-242.
29. Rezek M., Havlicek V., Hughes K. R., Friesen H. Cortical administration of somatostatin (SRIF). Effect on sleep and motor behavior Pharmacol. Biochem. Behav. 5:1976;73-77.
30. Rezek M., Havlicek V., Hughes K. R., Friesen H. Behavioral and motor excitation and inhibition induced by the administration of small and large doses of somatostatin into the amygdala. Neuropharmacology. 16:1976;157-160.
31. Sagar S. M., Landry D., Millard W. J., Badger T. M., Arnold M. A., Martin J. B. Depletion of somatostatin-like immunoreactivity in the rat central nervous system by cysteamine. J. Neurosci. 2:1982;225-231.
32. Swerdlow N. R., Geyer M. A. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol. Biochem. Behav. 44:1993;741-744.
33. Swerdlow N. R., Caine S. B., Braff D. L., Geyer M. A. The neural substrates of sensorimotor gating of the startle reflex. A review of recent findings and their implications J. Psychopharmacol. 6:1992;176-190.
34. Swerdlow N. R., Braff D. L., Taaid N., Geyer M. A. Assessing the validity of an animal model of sensorimotor gating deficits in schizophrenia. Arch. Gen. Psychiatry. 51:1994;139-154.
35. Szabo S., Reichlin S. Somatostatin in rat tissues is depleted by cysteamine administration. Endocrinology. 109:1981;2255-2257.
36. Tatsuoka Y., Riskind P. N., Beal M. F., Martin J. B. The effect of amphetamine on the in vivo release of dopamine, somatostatin, and neuropeptide Y from rat caudate nucleus. Brain Res. 411:1987;200-203.
37. Thoss V. S., Perez J., Duc D., Hoyer D. Embryonic and postnatal mRNA distribution of five somatostatin receptor subtypes in the rat brain. Neuropharmacology. 34:1995;1673-1688.
38. Vecsei L., Alling C., Widerlov E. Comparative studies of intracerebroventricularly administered cysteamine and pantethine in different behavioral tests and on brain catecholamines in rats. Arch. Pharmacodyn. Ther. 305:1990;140-151.
39. Vecsei L., Bollok I., Telegdy G. Comparative studies with cyclic and linear somatostatin on active avoidance behavior and open-field activity in rats. Acta Physiol. Hung. 61:1983;43-49.
40. Vecsei L., Kiraly C. S., Bollok I., Nagy A., Varga J., Penke B., Telegdy G. Comparative studies with somatostatin and cysteamine in different behavioral tests on rats. Pharmacol. Biochem. Behav. 21:1984;833-837.
41. Vecsei L., Kovacs G. L., Faludi M., Bollok I., Telegdy G. Dose-related effects of cysteamine treatment on hypothalamic and striatal dopamine, noradrenaline, and serotonin transmission. Acta Physiol. Hung. 66:1985;213-217.
42. Vecsei L., Schwarzberg H., Telegdy G. The effect of somatostatin on the self stimulation of rats. Neuroendocrinol. Lett. 4:1982;37-43.
43. Vincent S. R., Staines W. A., Fibiger H. C. Histochemical demonstration of separate populations of somatostatin and cholinergic neurons in the rat striatum. Neurosci. Lett. 35:1983;111-114.
44. Wehrenberg W. B., Benoit R., Baird A. Inhibitory effects of cysteamine on neuroendocrine function. Regul. Pept. 6:1983;137-145.
45. Wood P., Etienne P., Lal S., Gauthier S., Cajal S., Nair N. P. V. Reduced lumbar CSF somatostatin levels in Alzheimers' disease. Life Sci. 31:1982;2073-2079.